by Elec23 | Jul 30, 2026 | News&events, VisMederi
A new scientific publication from VisMederi has recently been published in Influenza and Other Respiratory Viruses. The study, “Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID-19 Booster Vaccination,” analyzed data from 3,066...
by Elec23 | Jul 27, 2026 | News&events, VisMederi
VisMederi announces the successful qualification of a standardized, high-throughput Luminescence Serum Bactericidal Assay (L-SBA) — a key milestone in supporting the evaluation of next-generation Shigella vaccines. This achievement reflects the strength of an...
by Elec23 | Jul 1, 2026 | News&events, VisMederi
First identified in Uganda in 2007, Bundibugyo ebolavirus is one of the species of the Ebola virus. Although it has historically shown a lower case fatality rate than some other Ebola virus species, typically between 25% and 40%, it remains a serious public health...
by Elec23 | Mar 11, 2026 | News&events, VisMederi
VisMederi highlighted its collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in the European Phase 1 clinical programme evaluating a universal influenza vaccine candidate formulated with...
by Elec23 | Dec 5, 2025 | News&events, VisMederi
A new scientific paper authored by Emanuele Montomoli and Claudia Maria Trombetta has just been published in Expert Review of Vaccines: “High-dose influenza vaccine: enhanced protection for the elderly.” The review highlights the added value of the high-dose influenza...
